BPH Clinical Trial
Official title:
A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation
Primary: To determine factors that affect absorption and serum levels of lycopene after
supplementation.
Secondary:
1. To evaluate general safety and tolerability of oral lycopene 15 or 30 mg per day for 12
weeks.
2. To determine lycopene effects on reducing serum levels of prostate specific antigen
(PSA) and on relieving lower urinary tract symptoms (LUTS) in relation to prostate
hypertrophy as evaluated by the International Prostate Symptom Score (I-PSS).
This is an uncontrolled intervention study in which eligible male subjects (N=60), after a two-week washout, will be randomized to receive lycopene either 15 or 30 mg per day for 12 weeks. About equal numbers of subjects will be randomized to either 15 or 30 mg of lycopene (about 30 subjects for each arm). The study is expected to be finished in 2 year. The study is expected to be finished in 2 year. Concerning an expected dropout rate of 10%, 66 subjects will be recruited for the study. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02974751 -
Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
|
||
Terminated |
NCT04398966 -
Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT04029012 -
Penthrox in Rezūm BPH
|
Phase 4 | |
Recruiting |
NCT03912558 -
Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in BPH Patients.
|
N/A | |
Completed |
NCT00527488 -
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
|
Phase 2 | |
Recruiting |
NCT06323109 -
US Imaging for the Assessment of LUTS
|
||
Completed |
NCT05628025 -
Simulation-Based Enucleation Training: Initial Experience Using 3D-printed Organ Phantoms
|
||
Completed |
NCT00407329 -
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT00256399 -
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)
|
N/A | |
Terminated |
NCT03994263 -
A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI
|
N/A | |
Completed |
NCT03772808 -
Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS)
|
N/A | |
Completed |
NCT05818670 -
Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study
|
Phase 4 | |
Withdrawn |
NCT02961114 -
Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04198103 -
Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT00696761 -
The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
|
Phase 4 | |
Completed |
NCT00199550 -
Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)
|
Phase 4 | |
Completed |
NCT02702947 -
Efficacy of Prunus Domestica Extract in BPH
|
Phase 4 | |
Completed |
NCT00037141 -
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05620784 -
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
|
Phase 3 | |
Not yet recruiting |
NCT05719220 -
Effect of Group Preoperative Pelvic Floor Training for HoLEP
|